Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Ph II CHOP+Velcade in Mediastinal LBCL
- Conditions
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00361621
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
- Conditions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00357084
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Lenalidomide for Patients With Myelofibrosis (MF)
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00352794
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00352027
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 37
- Registration Number
- NCT00350545
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2017-12-08
- Target Recruit Count
- 21
- Registration Number
- NCT00348816
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2006-09-26
- Lead Sponsor
- The Alvin and Lois Lapidus Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00333008
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Northwest Hospital Center, Randallstown, Maryland, United States
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00331344
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Conditions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Favrille
- Target Recruit Count
- 480
- Registration Number
- NCT00324831
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 150
- Registration Number
- NCT00324467
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.